狼疮治疗市场：依疾病类型、治疗药物类型、给药途径、通路、地区

预计2024年全球狼疮治疗市场规模为32.5亿美元，2031年将达59.1亿美元，2024年至2031年复合年增长率为8.9%。

图 1. 2024 年狼疮治疗药物市场占有率(%)（按地区）

由于全球狼疮盛行率不断上升，全球狼疮治疗市场在过去几年中稳步成长。狼疮是一种慢性自体免疫疾病，身体的免疫系统开始攻击自身的组织和器官。它通常影响育龄妇女，主要症状包括关节疼痛、皮疹、疲劳和器官发炎。据估计，大约有 150 万美国人和全世界至少 500 万人患有狼疮。政府和医疗组织加强对狼疮早期诊断和治疗药物的认识活动，进一步推动了市场成长。此外，正在进行的开发更安全、更有效的治疗方法的研究也促进了预测期内的市场成长。

市场动态：

全球狼疮治疗市场是由全球狼疮患病率不断上升、对狼疮认识的提高以及医疗保健支出的增加所推动的。据美国狼疮基金会称，美国每年报告约 16,000 例新患者。政府对狼疮治疗药物研发活动的有利支持也促进了市场成长。然而，高昂的药品成本和器官特异性狼疮药物的稀缺性是预计在一定程度上抑制市场成长的一些关键因素。同时，正在进行的新型生技药品和个人化医疗的临床试验将为未来几年的市场进入者提供利润丰厚的机会。

本研究的主要特点

• 该报告对全球狼疮治疗药物市场进行了详细分析，并提供了以2023年为基准年的预测期（2024-2031年）的市场规模（十亿美元）和年复合成长率（CAGR%）。
• 它还强调了各个细分市场的潜在收益成长机会，并说明了该市场有吸引力的投资提案矩阵。
• 它还提供了有关市场驱动因素、限制因素、机会、新产品发布和核准、市场趋势、区域前景、主要企业采取的竞争策略等的主要考察。
• 根据公司亮点、产品系列、主要亮点、绩效和策略等参数，对全球狼疮治疗药物市场的主要企业进行概况分析。
• 主要企业包括 Hikma Pharmaceuticals PLC、Dr. Reddy's Laboratories Ltd.、Amgen Inc.、Novartis AG、Sanofi、UCB SA、ImmuPharma PLC、Bayer AG、Merck &Co.、Aurinia Pharmaceuticals Inc.、Pfizer Inc.、AstraZeneca、F.。 Hoffmann-La Roche Ltd.、Bristol-Myers Squibb Company、Teva Pharmaceutical Industries Ltd.、Takeda Pharmaceutical Company Limited 和Boehringer Ingelheim International Gmbh。
• 该报告的见解使负责人和公司经营团队能够就未来的产品发布、升级、市场扩张和行销策略做出明智的决策。
• 全球狼疮治疗药物市场迎合了该行业的各种相关人员，如投资者、供应商、产品製造商、经销商、新进业者和财务分析师。
• 相关人员可以透过用于全球狼疮治疗药物市场分析的各种策略矩阵来促进他们的决策。

目录

第一章 研究目的与前提

• 研究目标
• 先决条件
• 简称

第二章 市场展望

• 报告说明
  • 市场定义和范围
• 执行概述
• 一致的机会地图 (COM)

第三章市场动态、法规及趋势分析

• 市场动态
  • 促进因素
  • 抑制因素
  • 机会
• 影响分析
• 流行病学
• 市场趋势
• 监管场景
• 製造商收益
• 收购和合作场景
• 产品发布/核准
• 资金筹措和投资
• PEST分析
• 波特的分析

第四章全球狼疮治疗市场 - 冠状病毒 (COVID-19) 大流行的影响

• 整体影响
• 政府倡议
• COVID-19 对市场的影响

第五章全球狼疮治疗市场，依疾病类型，2019-2031（十亿美元）

• 介绍
• 全身性红斑性狼疮（SLE）
• 皮肤红斑狼疮
• 药物性红斑狼疮
• 新生儿狼疮

第六章全球狼疮治疗市场，依治疗类型，2019-2031（十亿美元）

• 介绍
• 非类固醇消炎剂(NSAID)
• 生技药品
• 抗疟疾药
• 皮质类固醇
• 其他的

第七章 全球狼疮治疗市场，依给药途径，2019-2031 年（十亿美元）

• 介绍
• 口服
• 皮下的
• 静脉
• 其他的

第 8 章全球狼疮治疗市场，按分销管道划分，2019-2031 年（十亿美元）

• 介绍
• 医院药房
• 医疗用品店
• 其他的

第9章全球狼疮治疗市场，按地区，2019-2031（十亿美元）

• 介绍
• 拉丁美洲
• 欧洲
• 亚太地区

Global lupus therapeutic market is estimated to be valued at USD 3.25 Bn in 2024 and is expected to reach USD 5.91 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 8.9% from 2024 to 2031.

Figure 1. Lupus Therapeutic Market Share (%), By Region, 2024

The global lupus therapeutic market has been witnessing steady growth over the past few years owing to the rising prevalence of lupus disease globally. Lupus is a chronic autoimmune disorder where the immune system of the body starts attacking its own tissues and organs. It commonly affects women in their childbearing years and major symptoms include joint pain, rashes, fatigue, and organ inflammation. According to estimates, about 1.5 million Americans and at least 5 million people worldwide suffer from a form of lupus. Growing awareness initiatives by government and healthcare organizations regarding early diagnosis and treatment of lupus has further boosted the market growth. Moreover, ongoing research into developing safer and more effective therapeutic drugs will continue driving the market growth during the forecast period.

Market Dynamics:

The global lupus therapeutic market is driven by the growing prevalence of lupus globally, rising awareness initiatives regarding the disease, and increasing healthcare expenditure. As per the Lupus Foundation of America, around 16,000 new cases are reported in the U.S. every year. Favorable government support for research and development activities focused on lupus therapeutics is also propelling the market growth. However, high treatment cost and lack of drugs for organ-specific lupus are some of the key factors expected to restrain the market growth to a certain extent. On the other hand, ongoing clinical trials for novel biologic drugs and personalized medicine offer lucrative opportunities for market players in the coming years.

Key Features of the Study:

• This report provides an in-depth analysis of the global lupus therapeutic market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2024-2031), considering 2023 as the base year.
• It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market.
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players.
• It profiles key players in the global lupus therapeutic market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies.
• Key companies covered as a part of this includes Hikma Pharmaceuticals PLC, Dr. Reddy's Laboratories Ltd., Amgen Inc., Novartis AG, Sanofi, UCB S.A., ImmuPharma PLC, Bayer AG, Merck & Co., Inc., Aurinia Pharmaceuticals Inc., Pfizer Inc., AstraZeneca, F.Hoffmann-La Roche Ltd, Bristol-Myers Squibb Company, Teva Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, and Boehringer Ingelheim International Gmbh.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
• Global lupus therapeutic market caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global lupus therapeutic market.

Detailed Segmentation-

• By Disease Type:
  • Systemic Lupus Erythematosus (SLE)
  • Cutaneous Lupus Erythematosus
  • Drug-Induced Lupus Erythematosus
  • Neonatal Lupus
• By Treatment Type:
  • Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)
  • Biologics
  • Antimalarial Drugs
  • Corticosteroids
  • Others
• By Route of Administration:
  • Oral
  • Subcutaneous
  • Intravenous
  • Others
• By Distribution Channel:
  • Hospital Pharmacies
  • Medical Stores
  • Others
• By Region:
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East
  • Africa
• Company Profiles:
  • Hikma Pharmaceuticals PLC
  • Reddy's Laboratories Ltd.
  • Amgen Inc.
  • Novartis AG
  • Sanofi
  • UCB S.A.
  • ImmuPharma PLC
  • Bayer AG
  • Merck & Co., Inc.
  • Aurinia Pharmaceuticals Inc.
  • Pfizer Inc.
  • AstraZeneca
  • Hoffmann-La Roche Ltd
  • Bristol-Myers Squibb Company
  • Teva Pharmaceutical Industries Ltd.
  • Takeda Pharmaceutical Company Limited
  • Boehringer Ingelheim International Gmbh

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snapshot, By Disease Type
  • Market Snapshot, By Treatment Type
  • Market Snapshot, By Route of Administration
  • Market Snapshot, By Distribution Channel
  • Market Snapshot, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Opportunities
• Impact Analysis
• Epidemiology
• Market Trends
• Key Developments
• Regulatory Scenario
• Manufacturer Revenue
• Acquisitions and Partnerships Scenario
• Product Launches/Approvals
• Funding and Investments
• PEST Analysis
• Porter's Analysis

4. Global Lupus Therapeutic Market - Impact of Coronavirus (COVID-19) Pandemic

• Overall Impact
• Government Initiatives
• COVID-19 Impact on the Market

5. Global Lupus Therapeutic Market, By Disease Type, 2019 - 2031, (USD Bn)

• Overview
  • Market Share Analysis, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, 2019 - 2031
  • Segment Trends
• Systemic Lupus Erythematosus (SLE)
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Cutaneous Lupus Erythematosus
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Drug-Induced Lupus Erythematosus
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Neonatal Lupus
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

6. Global Lupus Therapeutic Market, By Treatment Type, 2019 - 2031, (USD Bn)

• Overview
  • Market Share Analysis, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, 2019 - 2031
  • Segment Trends
• Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Biologics
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Antimalarial Drugs
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Corticosteroids
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Others
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

7. Global Lupus Therapeutic Market, By Route of Administration, 2019 - 2031, (USD Bn)

• Overview
  • Market Share Analysis, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, 2019 - 2031
  • Segment Trends
• Oral
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Subcutaneous
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Intravenous
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Others
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

8. Global Lupus Therapeutic Market, By Distribution Channel, 2019 - 2031, (USD Bn)

• Overview
  • Market Share Analysis, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, 2019 - 2031
  • Segment Trends
• Hospital Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Medical Stores
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Others
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

9. Global Lupus Therapeutic Market, By Region, 2019 - 2031, (USD Bn)

• Introduction
  • Market Share Analysis, By Region, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, For Region, 2019-2031
  • Regional Trends
    • North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
    • U.S.
    • Canada
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • ASEAN
  • Australia
  • South Korea
  • Rest of Asia Pacific
• Middle East
  • GCC
  • Israel
  • Rest of Middle East
  • Africa
  • North Africa
  • Central Africa
  • South Africa

10. Competitive Landscape

• Company Profiles
  • Hikma Pharmaceuticals PLC
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Dr. Reddy's Laboratories Ltd.
  • Amgen Inc.
  • Novartis AG
  • Sanofi
  • UCB S.A.
  • ImmuPharma PLC
  • Bayer AG
  • Merck & Co., Inc.
  • Aurinia Pharmaceuticals Inc.
  • Pfizer Inc.
  • AstraZeneca
  • F.Hoffmann-La Roche Ltd
  • Bristol-Myers Squibb Company
  • Teva Pharmaceutical Industries Ltd.
  • Takeda Pharmaceutical Company Limited
  • Boehringer Ingelheim International Gmbh

11. Analyst Recommendations

• Wheel of Fortune
• Analyst View
• Coherent Opportunity Map

12. References and Research Methodology

• References
• Research Methodology
• About us and Sales Contact